Immunologically “hot” tumors with a high number of CD3+ and CD8+ T cells at the tumor center are more susceptible to agents targeting CTLA-4, PD-L1 and PD-1 that modulate T cell function [106,107]. The gene discussed is CD274; the disease is neoplasm.